Wezlana, ustekinumab-auub
Named-patient access overview. Wezlana is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Wezlana
Wezlana (ustekinumab-auub) is manufactured by Amgen and indicated for Biosimilar to Stelara — psoriasis, psoriatic arthritis, Crohn's, ulcerative colitis. It is an anti-IL-12/IL-23 monoclonal antibody (subcutaneous and IV) approved by the US FDA in 2023 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Wezlana
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Wezlana for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Wezlana is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Country coverage
Reserve Meds publishes detailed country deep-dives for our most-requested medications. Wezlana country deep-dives are not yet published; we are expanding coverage as the cohort grows. If you are pursuing Wezlana for a patient in the UAE, Saudi Arabia, India, Egypt, Pakistan, or another market we serve, submit a request and our clinical team will match the destination to the appropriate regulatory pathway and timeline.
Reserved for you. Wezlana is in coordination scope for the first cohort. Country-specific pricing and timing are confirmed once a coordinator reviews your case.
Start a request for Wezlana
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.